Research Topics
Genomes and Genes | P E LønningSummaryAffiliation: Haukeland University Hospital Country: Norway Publications
| Collaborators
|
Detail Information
Publications
Aromatase inhibitors and inactivators for breast cancer therapyPer E Lønning
Section of Oncology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
Drugs Aging 19:277-98. 2002..In addition, these novel compounds with lack of complete cross-resistance extend the scope of using sequential treatment options to maximise the duration of optimal endocrine therapy in metastatic breast cancer disease...
Aromatase inhibitors and inactivators for breast cancer treatmentP E Lonning
Department of Oncology, Institute of Medicine, Haukeland University Hospital, Bergen, Norway
Eur J Cancer 38:S47-8. 2002
The role of aromatase inactivators in the treatment of breast cancerPer Eystein Lønning
Department of Oncology, Haukeland Hospital, University of Bergen, N 5021 Bergen, Norway
Int J Clin Oncol 7:265-70. 2002..The results from these studies will outline the potential role of exemestane in adjuvant treatment and, potentially, for breast-cancer prevention in postmenopausal women...
Exemestane in breast cancer: current status and future directionsP E Lønning
Section of Oncology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
Clin Breast Cancer 1:S28-33. 2000..The findings from these studies will determine the role of exemestane in early breast cancer and lay the foundation for assessing its potential role in breast cancer prevention...
The potential for aromatase inhibition in breast cancer preventionP E Lønning
Section of Oncology, Institute of Medicine, Haukeland University Hospital, Bergen, Norway
Clin Cancer Res 7:4423s-4428s; discussion 4411s-4412s. 2001..Results from ongoing studies examining the toxicity of aromatase inhibitors and inactivators in postmenopausal women will set the stage for future trials that explore them as preventive treatment options...
Stepwise estrogen suppression manipulating the estrostatP E Lønning
Section of Oncology, Department of Medicine, Haukeland University Hospital, 5021, Bergen, Norway
J Steroid Biochem Mol Biol 79:127-32. 2001..Future studies are warranted to explore alterations in gene expression and signaling mechanisms in response to different therapies in tumor tissue in vivo...
Microarrays in primary breast cancer--lessons from chemotherapy studiesP E Lønning
Section of Oncology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
Endocr Relat Cancer 8:259-63. 2001..This paper outlines our continuing studies exploring prognostic and, we hope, predictive factors in breast cancer therapy...
Pharmacology and clinical experience with exemestaneP E Lønning
Department of Medicine, Section of Oncology, Haukeland University Hospital, N 5021, Bergen, Norway
Expert Opin Investig Drugs 9:1897-905. 2000..Sequential therapy with tamoxifen followed by exemestane is also being compared with tamoxifen monotherapy in the adjuvant setting. In addition, the drug may have potential for breast cancer prevention...
Clinico-pharmacological aspects of different hormone treatmentsP E Lønning
Department of Oncology, Haukeland University Hospital, N 5021, Bergen, Norway
Eur J Cancer 36:S81-2. 2000..Faslodex, the first representative of the so-called 'pure' oestrogen antagonists, has shown beneficial effects in patients resistant to tamoxifen [4]...
Is there a growing role for endocrine therapy in the treatment of breast cancer?P E Lønning
Department of Medicine, Haukeland University Hospital, Bergen, Norway
Drugs 60:11-21. 2000....
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trialP E Lønning
Department of Oncology, Haukeland University Hospital, Bergen, Norway
J Clin Oncol 18:2234-44. 2000....
Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?P E Lønning
Section of Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, Jonas Lies vei 26, N 5021 Bergen, Norway
J Steroid Biochem Mol Biol 118:288-93. 2010..Ongoing studies exploring tissue estrogen levels as well as gene expression profiles on therapy may further improve this important therapeutic area...
Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patientsJ Geisler
Department of Oncology, Haukeland University Hospital, Bergen, Norway
J Clin Endocrinol Metab 83:2687-93. 1998..54 and 1.27 nmol/L during treatment with D-AG and DL-AG, respectively; P < 0.05)...
Aromatase inhibitors and their future role in post-menopausal women with early breast cancerP E Lønning
Department of Therapeutic Oncology and Radiophysics, Haukeland University Hospital, Bergen, Norway
Br J Cancer 78:12-5. 1998..The results of these trials will help to determine whether anastrozole has any benefits over tamoxifen, the current treatment of choice in post-menopausal women with early breast cancer...
Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor statusP E Lønning
Section of Oncology, Institute of Medicine, University of Bergen, Jonas Lies vei 26, N 5021 Bergen, Norway
J Steroid Biochem Mol Biol 117:31-41. 2009..A possible explanation to our finding is increased ligand receptor binding capacity for E(2) in receptor positive tumours but alternative factors influencing intratumour estrogen disposition cannot be excluded...
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapyP E Lønning
Department of Medicine, Haukeland University Hospital, Bergen, Norway
Breast Cancer Res Treat 67:111-6. 2001..Such treatment represents a valuable alternative to chemotherapy in selected patients...
Aromatase inhibition for breast cancer treatmentP E Lønning
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Acta Oncol 35:38-43. 1996....
The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuumP E Lønning
Section of Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, Bergen, Norway
Ann Oncol 22:503-14. 2011..This article examines the clinical data with aromatase inhibitors, following a brief summary of their pharmacology...
Pharmacokinetics and metabolism of formestane in breast cancer patientsP E Lønning
Department of Oncology, Haukeland Hospital, University of Bergen, N 5021 Bergen, Norway
J Steroid Biochem Mol Biol 77:39-47. 2001..These exocons are formed by stereoselective 3-keto reduction, accompanied by reduction of the 4,5-enol function. The exocons do not inhibit human placental aromatase activity in vitro...
Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitorsM Hauglid Flågeng
Institute of Medicine, University of Bergen, Bergen, Norway
Br J Cancer 101:1253-60. 2009..Characterisation of the molecular response to aromatase inhibitors in breast cancer tissue may provide important information regarding development of oestrogen hypersensitivity...
Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancerL A Akslen
The Gade Institute, Section for Pathology, University of Bergen, Haukeland University Hospital, Bergen N 5021, Norway
Br J Cancer 105:9-12. 2011..Glomeruloid microvascular proliferation (GMP), a novel histology-based angiogenesis marker, has been associated with decreased survival in several human cancers...
Bone safety of aromatase inhibitors versus tamoxifenP E Lønning
Department of Medicine, Section of Oncology, Haukeland University Hospital, Bergen, Norway
Int J Gynecol Cancer 16:518-20. 2006..While an increased fracture rate may have detrimental effects, evidence suggests that enhanced bone loss may be preventable through careful bone mineral density (BMD) assessment and treatment with bisphosphonates...
Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancerP E Lønning
Section of Oncology, Institute of Medicine, University of Bergen, Haukeland University Hospital, Bergen, Norway
Ann Oncol 17:217-25. 2006..Any difference in cost/utility between the strategies may be of importance to therapy selection...
Influence of droloxifene on metastatic breast cancer as first-line endocrine treatmentH Haarstad
Department of Oncology, Trondheim University Hospital, Norway
Acta Oncol 37:365-8. 1998..The response to droloxifene recorded in the present study is in accordance with the response rates to tamoxifen as first-line treatment in identical groups of patients...
Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysisJ Norum
Department of Oncology, University Hospital of North Norway, Tromsø, Norway
Acta Oncol 46:153-64. 2007..Sensitivity analyses documented survival gain, price of trastuzumab, production gain and discount rate to be the major factors influencing cost-effectiveness ratio. Trastuzumab is indicated cost effective in Norway...
Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?P E Lønning
Section of Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, N 5021 Bergen, Norway
Eur J Cancer 45:527-35. 2009..Neither do we know whether some tumours are more sensitive to particular drugs. This paper summarizes clinical findings up to now with respect to lack of cross-resistance and discuss potential mechanisms involved...
Breast cancer prognostication and prediction in the postgenomic eraP E Lønning
Section of Oncology, Institute of Medicine, University of Bergen, Norway
Ann Oncol 18:1293-306. 2007..On the basis of these findings, we suggest drug resistance may be explored on the basis of upfront biological hypotheses...
Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimideP E Lønning
Department of Therapeutic Oncology and Radiophysics, University of Bergen, Norway
Br J Cancer 60:107-11. 1989..The possibility that such effects might be partly responsible for the mechanism of action of aminoglutethimide in advanced breast cancer should be considered...
RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancerS Knappskog
Department of Molecular Biology, University of Bergen, Bergen, Norway
Ann Oncol 22:2208-15. 2011....
Breast cancer prognostication and prediction: are we making progress?P E Lønning
Institute of Medicine, University of Bergen, Department of Oncology, Haukeland University Hospital, Bergen, Norway
Ann Oncol 18:viii3-7. 2007..This article will focus on recent advances in prognostication and prediction, with emphasis on findings from gene expression profiling studies...
Aromatase inhibitors in breast cancerP E Lønning
Section of Oncology, Institute of Medicine, Haukeland University Hospital, University of Bergen, 5021 Bergen, Norway
Endocr Relat Cancer 11:179-89. 2004..Interesting findings such as the lack of cross-resistance between steroidal and non-steroidal compounds should be further explored, as this may add additional information to our understanding of breast cancer biology...
The insulin-like growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression, and antiretroviral therapyS I Helle
Department of Oncology, Haukeland University Hospital, N 5021 Bergen, Norway
J Clin Endocrinol Metab 86:227-33. 2001..Our results reveal several alterations in the IGF system during HIV infection with decreased IGF-II levels, increased concentration of IGFBP-2, and an increased IGFBP-3 protease activity in advanced disease...
Treatment of early breast cancer with conservation of the breast. A reviewP E Lønning
Department of Oncology and Radiophysics, Haukeland Sykehus, Bergen, Norway
Acta Oncol 30:779-92. 1991..The need for radiotherapy after local excision for small intraductal (ductal carcinoma in situ) cancers is being addressed in ongoing trials...
Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemiaN Anensen
Hematology Section, Institute of Medicine, University of Bergen, Bergen, Norway
Oncogene 31:1533-45. 2012..In contrast, mutated NPM1, a prognostic marker for long-term survival, correlated with p53 isoforms β and γ expression. In conclusion, p53 biosignatures contain useful information for cancer evaluation and prognostication...
The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signalingM Chekenya
Norlux Neuro Oncology Group, Department of Biomedicine, University of Bergen, Bergen, Norway
Oncogene 27:5182-94. 2008..Thus, as a novel regulator of the antiapoptotic response, NG2/MPG may represent an effective therapeutic target in several cancer subtypes...
